Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports

(2011) Noritoshi Yoshii et al.   ANTI-CANCER DRUGS

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data

(2011) Fredrik Nyberg et al.   PHARMACOGENOMICS

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

(2010) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event

(2009) Shotaro Ide et al.   LUNG CANCER

Drug-Induced Interstitial Lung Diseases Associated with Molecular-Targeted Anticancer Agents

(2009) Akihiko Gemma   JOURNAL OF NIPPON MEDICAL SCHOOL

Interstitial Lung Disease in Japanese Patients with Lung Cancer

(2008) Shoji Kudoh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE